Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).

被引：3
|
作者：
Nokihara, Hiroshi
Katakami, Nobuyuki
Hida, Toyoaki
Imamura, Fumio
Sakai, Hiroshi
Atagi, Shinji
Nishio, Makoto
Helwig, Christoph
Achiwa, Hiroyuki
Tamura, Tomohide
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
[3] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[4] Osaka Med Ctr, Osaka, Japan
[5] Saitama Canc Ctr, Saitama, Japan
[6] Kinki Chuo Chest Med Ctr, Osaka, Japan
[7] Japanese Fdn Canc Res, Tokyo, Japan
[8] Merck KGaA, Darmstadt, Germany
[9] Merck Serono Co Ltd, Tokyo, Japan
[10] St Lukes Int Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
    Katakami, Nobuyuki
    Hida, Toyoaki
    Nokihara, Hiroshi
    Imamura, Fumio
    Sakai, Hiroshi
    Atagi, Shinji
    Nishio, Makoto
    Kashii, Tatsuhiko
    Satouchi, Miyako
    Helwig, Christoph
    Watanabe, Morihiro
    Tamura, Tomohide
    LUNG CANCER, 2017, 105 : 23 - 30
  • [2] Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
    Wauters, Els
    Vansteenkiste, Johan
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 574 - 577
  • [3] Cisplatin and gemcitabine (GC) as neoadjuvant therapy of stage III unresectable non-small cell lung cancer (NSCLC):: A phase II study
    Mazzoni, F
    Di Stefano, A
    Maestri, A
    Calandri, C
    Mosconi, AM
    De Marinis, F
    Scagliotti, GV
    Selvaggi, G
    Crinò, L
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 8 - 8
  • [4] Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study
    Khandekar, Melin J.
    Jain, Rakesh
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S16 - S20
  • [5] Phase II trial of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC).
    Crino, L
    Mazzoni, F
    Maestri, A
    Calandri, C
    Selvaggi, G
    Scagliotti, GV
    De Marinis, F
    Gregorc, V
    Darwish, S
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 108 - 108
  • [6] Preoperative chemoradiotherapy for stage III unresectable non-small cell lung cancer: Results of a phase II study.
    Reboul, F
    Chauvin, G
    Vincent, P
    Brewer, Y
    FelixFaure, C
    Taulelle, M
    BULLETIN DU CANCER, 1996, 83 (04) : 300 - 306
  • [7] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [8] Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Peters, Solange
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1986 - 1988
  • [9] Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer
    Grossi, F
    Pennucci, MC
    Serrano, J
    Frola, C
    Mereu, C
    Scolaro, T
    Ratto, GB
    Tixi, L
    Ardizzoni, A
    ANTICANCER RESEARCH, 2002, 22 (6B) : 3519 - 3524
  • [10] Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study
    Xu, Yaping
    Ma, Shenglin
    Ji, Yongling
    Sun, Xiaojiang
    Jiang, Hao
    Chen, Jianxiang
    Du, Xianghui
    Zheng, Yuanda
    Qiu, Guoqin
    LUNG CANCER, 2011, 72 (03) : 327 - 332
12345